

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6456828

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LES LABORATOIRES SERVIER	11/21/2014
RECEIVING PARTY DATA	
Name:	PHARMACYCLICS, INC.
Street Address:	995 E. ARQUES AVE.
City:	SUNNYVALE
State/Country:	CALIFORNIA
Postal Code:	94085
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16676911
CORRESPONDENCE DATA	
Fax Number:	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 832-1286
Email:	patentdocketing@foleyhoag.com, cmurphy@foleyhoag.com
Correspondent Name:	FOLEY HOAG LLP
Address Line 1:	155 SEAPORT BOULEVARD
Address Line 4:	BOSTON, MASSACHUSETTS 02210-2600
ATTORNEY DOCKET NUMBER:	XPR-32202
NAME OF SUBMITTER:	CARA MURPHY
SIGNATURE:	/Cara Murphy/
DATE SIGNED:	12/17/2020
Total Attachments: 18	
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page1.tif	
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page2.tif	
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page3.tif	
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page4.tif	
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page5.tif	
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page6.tif	

source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page7.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page8.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page9.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page10.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page11.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page12.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page13.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page14.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page15.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page16.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page17.tif
source=XPR_32202_Executed_Assignment_Servier_to_Pharmacyclics_Inc#page18.tif

Original

142154/ML/NM

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (this "Assignment") is dated as of November 21st, 2014 (the "Effective Date"), and is entered into between Les Laboratoires Servier, having its place of business at 50 Rue Carnot, 92150 Suresnes, France ("Servier") and Pharmacyclics, Inc., a Delaware corporation, having its place of business at 995 East Arques Avenue, Sunnyvale, California 94085, USA ("Pharmacyclics").

WHEREAS, Servier and Pharmacyclics entered into a Collaboration Agreement dated April 9, 2009 (the "Collaboration Agreement"), whereby Servier and Pharmacyclics agreed to collaborate on the development of pan-HDAC inhibitors;

WHEREAS, the Collaboration Agreement is terminated as of November 23, 2014; and


WHEREAS, Servier has agreed to assign all of its right, title and interest in and to any patents and patent applications developed pursuant to the Collaboration Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Servier hereby sells, assigns, transfers and sets over to Pharmacyclics and its successors, assigns and other legal representatives all of Servier's right, title and interest in and to the patents and patent applications disclosed in Schedule A attached hereto ("the "Schedule A Patent Rights") and Schedule B attached hereto ("the "Schedule B Patent Rights"), including for clarity, (a) in and to all embodiments of any inventions in the Schedule A Patent Rights and the Schedule B Patent Rights, (b) the right to claim priority to and from the Schedule A Patent Rights and the Schedule B Patent Rights, (c) in and to each and every application that is a divisional, substitution, continuation, continuation-in-part or national stage filing of any of the Schedule A Patent Rights or the Schedule B Patent Rights, (d) in and to each and every patent issuing or reissuing from any of the foregoing, (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing, (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing now or hereafter in effect, and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Pharmacyclics' own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Schedule A Patent Rights and/or the Schedule B Patent Rights (altogether referred to as the "Patent Rights"), for Pharmacyclics' own use and enjoyment, and for the use and enjoyment of Pharmacyclics' successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Servier if this assignment and sale had not been made.

Servier authorizes and requests the United States Commissioner of Patents and Trademarks and any other applicable non-United States government authorities record Pharmacyclics as the sole assignee and owner of the Schedule A Patent Rights and the Schedule B Patent Rights, and issue any and all registrations thereon solely to Pharmacyclics, as sole assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Pharmacyclics and its successors, assigns or other legal representatives.

Servier shall provide, or cause its current or former employees or consultants to provide, to Pharmacyclics, its successors, assigns or other legal representatives, cooperation and assistance at Pharmacyclics' request and expense but without additional compensation, (including, without limitation, the execution and delivery of any and all affidavits, declarations, oaths, samples, exhibits, and other



PATENT

REEL: 054684 FRAME: 0926

documentation as may be reasonably required) in connection with (1) preparation, prosecution, reexamination, or reissue of any patent or application within the Schedule A Patent Rights and the Schedule B Patent Rights that Pharmacyclics may reasonably deem appropriate that may be secured under the laws now or hereafter in effect in the United States or any foreign countries; (2) prosecution or defense of any cancellation, opposition, *inter partes* review, post grant review, infringement or other proceedings that may arise in connection with any of the Schedule A Patent Rights or the Schedule B Patent Rights, including, without limitation, testifying as to any facts relating to the Schedule A Patent Rights, the Schedule B Patent Rights and this Assignment; (3) enforcement of Pharmacyclics' rights in any Schedule A Patent Rights or the Schedule B Patent Rights; and (4) implementation, perfection and/or recording of this Assignment.

This Assignment will inure to the benefit of Pharmacyclics, its successors and assigns, and will bind Servier and its successors and permitted assigns, except that Servier may not assign this Assignment without the consent of Pharmacyclics. This Assignment will be governed in all respects, whether as to validity, construction, capacity, performance or otherwise, by the laws of France without reference to its conflicts of law provisions. If any term or provision of this Assignment will, to any extent or for any reason, be held to be invalid or unenforceable, the remainder of this Assignment will not be affected thereby and will be construed as if such invalid or unenforceable provision had never been contained herein or been applicable in such circumstances. This Assignment may not be amended unless mutually agreed upon in writing by both Pharmacyclics and Servier, and no waiver will be effective unless signed by Pharmacyclics.

The Patent Rights are assigned by Servier to Pharmacyclics on an "as is" basis, without any representations or warranties, express or implied, of any kind, and Servier expressly disclaims all such representations and warranties to the maximum extent permitted under applicable law. Pharmacyclics, on behalf of itself and its affiliates, sublicensees, successors, assigns and other legal representatives, accepts all risk and liability in relation to the use of the Patent Rights received from Servier under this Agreement

[The remainder of the page left blank intentionally; signature page follows]



IN WITNESS WHEREOF, Servier has caused this Assignment to be duly executed as of the date first above written.

Date: November 21st, 2014

[Handwritten signature]

Sylvie JAGUELIN
Patent Director

CERTIFICATION DE SIGNATURE
M^r François GULLERMANN
Notaire à SURES (92)
certifie UNIQUEMENT que la
signature apposée ci-contre est
celle de M. JAGUELIN

Le notaire ne certifie ni la
validité ni l'efficacité du présent
document, ni même le capacité
juridique du signataire pour
signer ce document.
Fait le 21/11/14

BAZANTAY



[Handwritten signature]
Christian BAZANTAY
Proxy

[[Servier: Please insert official notaire language]]

[Handwritten signature]

RECEIVED AND AGREED TO BY PHARMACYCLICS:

Date: 3 Dec, 2014

[Handwritten signature]

[[Name of Pharmacyclics Representative]]

[[Title of Pharmacyclics Representative]]


State of CALIFORNIA)

) SS:

County of SANTA CLARA)

On this the 3 day of DECEMBER, 2014, RICHARD B. LOE personally appeared before me, to me known to be the person named in and who executed the above Assignment individually, and acknowledged to me that he executed the same for the uses and the purposes therein mentioned.

SEAL



[Handwritten signature]

NOTARY PUBLIC

[The remainder of the page is blank and notary, witness signature page follows]

STATEMENT BY WITNESS:

Caroline
I, SULTANCI (name of witness), whose full post office address is 35 rue de Verdun Surmer
(address of witness) was personally present and did see Sylvie
JAGUEN (name of representative for
Servier) execute the above assignment.

Date: 21 Nov, 2014

Sultanci

[[Name of Servier Witness 1]]

STATEMENT BY WITNESS:

Christine
I, BRUNEL (name of witness), whose full post office address is 35 rue de Verdun - Surmer
(address of witness) was personally present and did see Sylvie
JAGUEN (name of representative for
Servier) execute the above assignment.

Date: 21 Nov, 2014

Christine Brunel

[[Name of Servier Witness 2]]

STATEMENT BY WITNESS:

I, Janet Bodwin (name of witness), whose full post office address is 999 E. Argue Ave.
(address of witness) was personally present and did see Richard R.
LOVE (name of representative for
Pharmacyclics) execute the above assignment.

Date: 3 Dec, 2014

Janet Bodwin

[[Name of PCYC Witness 1]]

STATEMENT BY WITNESS:

RAMANORAT
I, WASANE (name of witness), whose full post office address is 999 E. ARGUES AVE.
(address of witness) was personally present and did see RICHARD R.
LOVE (name of representative for
Pharmacyclics) execute the above assignment.

Date: 3 Dec, 2014

R. Wasane

[[Name of PCYC Witness 2]]

STATEMENT BY WITNESS:

Caroline
I, SUSTAND (name of witness), whose full post office address is 35 rue de Verdun, Suresnes
(address of witness) was personally present and did see Christophe (name of representative for
Servier) execute the above assignment.

Date: 21 Nov, 2014

Christophe

[[Name of Servier Witness 1]]

STATEMENT BY WITNESS:

Christine
I, BOUNEL (name of witness), whose full post office address is 35 rue de Verdun, Suresnes
(address of witness) was personally present and did see Christophe (name of representative for
Servier) execute the above assignment.

Date: 21 Nov, 2014

Christine
Christophe

Christine BOUNEL
[[Name of Servier Witness 2]]

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.871	Argentina	201110103321	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.681	Australia	2011376953	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.701	Canada	2,845,806	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.711	China	201180074826.7	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.611	European Patent Convention	11872389.9	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.761	Japan	2014-530636	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.771	Republic of Korea	10-2014-7007117	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.781	Mexico	MX/a/2014/002942	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.791	New Zealand	621221	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.601	Patent Cooperation Treaty	PCT/US2011/051470	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.811	Russian Federation	2014111069	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.821	Singapore	2014014419	13-Sep-2011

Servier to Pharmacyclics Assignment

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.841	South Africa	2014/01329	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.931	Ukraine	a2014 02905	13-Sep-2011
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF	25922-775.831	United States of America	14/344,314	11-Mar-2014

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
HDACI DOSAGE	25922-843.871	Argentina	P12 01 03299	07-Sep-2012
HDACI DOSAGE	25922-843.681	Australia	2012306122	07-Sep-2012
HDACI DOSAGE	25922-843.141	Bolivia	SP 00331-2012	07-Sep-2012
HDACI DOSAGE	25922-843.701	Canada	2,847,011	07-Sep-2012
HDACI DOSAGE	25922-843.711	China	201280041854.3	07-Sep-2012
HDACI DOSAGE	25922-843.611	European Patent Convention	12769146.7	07-Sep-2012
HDACI DOSAGE	25922-843.631	France	11/02727	08-Sep-2011
HDACI DOSAGE	25922-843.9661	Gulf Cooperation Council	2012/22190	05-Sep-2012
HDACI DOSAGE	25922-843.761	Japan	2014-529056	07-Sep-2012
HDACI DOSAGE	25922-843.9681	Jordan	238/2012	26-Aug-2012
HDACI DOSAGE	25922-843.771	Republic of Korea	10-2014-7009191	07-Sep-2012
HDACI DOSAGE	25922-843.351	Kosovo	KP/P/2012/50	07-Sep-2012
HDACI DOSAGE	25922-843.9691	Lebanon	9768	31-Aug-2012

Servier to Pharmacyclis Assignment

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
HDACi DOSAGE	25922-843.781	Mexico	mx/a/2014/002663	07-Sep-2012
HDACi DOSAGE	25922-843.791	New Zealand	622112	07-Sep-2012
HDACi DOSAGE	25922-843.9721	Pakistan	592/2012	03-Sep-2012
HDACi DOSAGE	25922-843.171	Panama	89842	07-Sep-2012
HDACi DOSAGE	25922-843.181	Paraguay	42154	07-Sep-2012
HDACi DOSAGE	25922-843.601	Patent Cooperation Treaty	PCT/FR2012/052004	07-Sep-2012
HDACi DOSAGE	25922-843.811	Russian Federation	2014 113 399	07-Sep-2012
HDACi DOSAGE	25922-843.9731	Saudi Arabia	112 33 0827	07-Sep-2012
HDACi DOSAGE	25922-843.821	Singapore	11201400120U	07-Sep-2012
HDACi DOSAGE	25922-843.841	South Africa	2014/01710	07-Sep-2012
HDACi DOSAGE	25922-843.851	Taiwan	101132604	06-Sep-2012
HDACi DOSAGE	25922-843.931	Ukraine	a 201403500	07-Sep-2012
HDACi DOSAGE	25922-843.101	United States of America	61/573,585	08-Sep-2011

Servier to Pharmacyclics Assignment

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
HDACi DOSAGE	25922-843.201	United States of America	13/605,116	06-Sep-2012
HDACi DOSAGE	25922-843.9761	Uruguay	34295	28-Aug-2012
HDACi DOSAGE	25922-843.9771	Venezuela	2012-001068	27-Aug-2012

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
METHODS OF TREATING NPG CANCER	25922-851.871	Argentina	P 12 01 04910	21-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.141	Bolivia	SP 00472-2012	21-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.631	France	11/04067	23-Dec-2011
METHODS OF TREATING NPG CANCER	25922-851.9661	Gulf Cooperation Council	2012/23172	22-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.9681	Jordan	376/2012	11-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.351	Kosovo	KS/P/2012/89	21-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.9691	Lebanon	9874	17-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.9721	Pakistan	868/2012	20-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.171	Panama	89906	19-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.181	Paraguay	60243/2012	21-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.601	Patent Cooperation Treaty	PCT/FR2012/000550	21-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.9731	Saudi Arabia	112 34 0131	22-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.851	Taiwan	101149177	21-Dec-2012

Servier to Pharmacyclics Assignment

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
METHODS OF TREATING NPG CANCER	25922-851.9761	Uruguay	34533	19-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.9771	Venezuela	2012-001668	18-Dec-2012
METHODS OF TREATING NPG CANCER	25922-851.101	United States of America	61/579,781	23-Dec-2011

Servier to Pharmacyclics Assignment

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
COMBINATION OF HDAC INHIBITORS AND FOLFOX	25922-862.871	Argentina	P120102390	02-Jul-2012
COMBINATION OF HDAC INHIBITORS AND FOLFOX	25922-862.611	European Patent Convention	12743494.2	03-Jul-2012
COMBINATION OF HDAC INHIBITORS AND FOLFOX	25922-862.631	France	11/02087	04-Jul-2011
COMBINATION OF HDAC INHIBITORS AND FOLFOX	25922-862.601	Patent Cooperation Treaty	PCT/FR2012/051540	03-Jul-2012
COMBINATION OF HDAC INHIBITORS AND FOLFOX	25922.862.831	United States of America	14/130,134	03-Jul-2012
COMBINATION OF HDAC INHIBITORS AND FOLFOX	25922-862.101	United States of America	61/571,789	05-Jul-2011

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
ABEXINOSTAT TOSYLATE SALT	25922-897.871	Argentina	P14 01 00648	28-Feb-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.141	Bolivia	SP 00061-2014	28-Feb-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.631	France	1351898	04-Mar-2013
ABEXINOSTAT TOSYLATE SALT	25922-897.9661	Gulf Cooperation Council	2014/26574	03-Mar-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.9681	Jordan	40/2014	18-Feb-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.351	Kosovo	KS/P/2014/22	03-Mar-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.9691	Lebanon	10274	25-Feb-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.9721	Pakistan	112/2014	25-Feb-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.181	Paraguay	8589/2014	03-Mar-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.601	Patent Cooperation Treaty	PCT/FR2014/050455	03-Mar-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.851	Taiwan	103107081	03-Mar-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.101	United States of America	61/772,191	04-Mar-2013

Servier to Pharmacyclics Assignment

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
ABEXINOSTAT TOSYLATE SALT	25922-897.201	United States of America	14/195,186	03-Mar-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.9761	Uruguay	35356	27-Feb-2014
ABEXINOSTAT TOSYLATE SALT	25922-897.9771	Venezuela	2014-000225	26-Feb-2014

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
NOUVEAUX SELS DE 3- [[DIMETHYLAMINO]METHYL]-N-(2-[4- (HYDROXYCARBAMOYL)PHENOXY]ETHYL)- 1-BENZOFURANE-2-CARBOXAMIDE, FORMES CRISTALLINES ASSOCIEES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT		France	1458215	3-Sep-14

Schedule A

Title	WSGR Docket Number	Country	App. Number	Filing Date
NOUVEAU SEL DE 3- [(DIMETHYLAMINO)METHYL]-N-(2-[4- (HYDROXYCARBAMOYL)PHENOXY]ETHYL)- 1-BENZOFURANE-2-CARBOXAMIDE, FORMES CRISTALLINES ASSOCIEES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT		France	1458224	3-Sep-14

Schedule B

Title	WSGR Docket Number	Country	App. Number	Filing Date
BIOMARKERS FOR THE IDENTIFICATION OF CHEMOSENSITIVITY		PCT	PCT/EP2014/056780	04-Apr-2014
BIOMARKERS FOR THE IDENTIFICATION OF CHEMOSENSITIVITY		European Patent Convention	13305443.7	05-Apr-2013

Servier to Pharmacyclics Assignment